Purchase this article with an account.
Marina Milenkovic, Nancy Brady, Anthony Lam; Antimicrobial Efficacy of New Investigational Multipurpose Disinfecting Solution and Comparison to Commercially Available Multipurpose Disinfecting Solutions. Invest. Ophthalmol. Vis. Sci. 2013;54(15):516. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate antimicrobial efficacy of investigational multipurpose formulation against bacteria, fungi and Acanthamoeba spp. and compare it to commercially available multipurpose disinfecting solutions (MPS). Study was done according to ISO 14729:2001/A.2010 standard.
The multipurpose disinfecting solutions studied were - Investigational MPS-1: polyhexamethylene biguanide (PHMB) + poloxamer (PLX) and currently marketed Japan products MPS-2: polyquaternium (PQ1) + tetronic 1304, MPS-3: PHMB + poloxamine (PLA) and MPS-4: PHMB +PLX. Test organisms were: Staphylococcus aureus (ATCC 6538), Pseudomonas aeruginosa (ATCC 9027), Serratia marcescens (ATCC 13880), Candida albicans (ATCC 10231), Fusarium solani (ATCC 36031) and Gram-negative clinical isolates. Test solutions were evaluated at the minimum recommended disinfection time of 4 hours. Disinfectant efficacy of MPS was also evaluated against Acanthamoeba trophozoites.
After 4 hours exposure, Investigational MPS-1 and MPS-3 showed >3 log kill of ISO bacteria and fungi. MPS-2 and MPS-4 failed to meet stand-alone criteria for ISO bacteria and fungi. MPS-1, MPS-3 and MPS-4 showed >3 log kill against clinical isolates, while MPS-2 showed <1 log kill. MPS-1 and MPS-3 achieved >3 log reduction for Acanthamoeba trophozoites, while MPS-4 achieved <2 log reduction and MPS-2 achieved <1 log reduction.
New Investigational MPS-1 exhibited broad antimicrobial activity against ISO panel organisms and showed additional robustness against clinical isolates and Acanthamoeba trophozoites. MPS-1 showed similar activity as MPS-3, while MPS-2 and MPS-4 failed to meet stand-alone criteria against ISO organisms and clinical isolates.
This PDF is available to Subscribers Only